We can stop this epidemic

The Guardian reports that the drug pipeline for TB is the best it has ever been, with 10 drugs in clinical testing. Delamanid is currently undergoing review by the European Medicines Agency. This follows closely on the heels of the US Food and Drug Administration approval of bedaquiline in late 2012, the first dedicated new TB drug since 1963. Both drugs are completely new classes of antibiotics with no reported resistance, and represent an unprecedented opportunity to improve treatment for drug-resistant TB. Read the full article.

Comments are closed.